|
gptkbp:instanceOf
|
gptkb:protein
gptkb:drug
cytokine
|
|
gptkbp:administeredBy
|
injection
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
gptkb:L03AB05
|
|
gptkbp:brand
|
gptkb:Roferon-A
Intron A
|
|
gptkbp:contraindication
|
autoimmune hepatitis
decompensated liver disease
|
|
gptkbp:discoveredIn
|
1980s
|
|
gptkbp:eliminationHalfLife
|
2-3 hours
|
|
gptkbp:gene
|
IFNA2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
interferon alpha-2b
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits viral replication
modulates immune response
antiproliferative effects
|
|
gptkbp:metabolism
|
gptkb:kidney
|
|
gptkbp:molecularWeight
|
19,271 Da
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:producedBy
|
gptkb:Bacteria
recombinant DNA technology
|
|
gptkbp:routeOfAdministration
|
intramuscular
subcutaneous
intravenous
|
|
gptkbp:sideEffect
|
gptkb:depression
gptkb:anemia
fatigue
neutropenia
thrombocytopenia
flu-like symptoms
|
|
gptkbp:UNII
|
gptkb:P18312
|
|
gptkbp:usedFor
|
gptkb:chronic_myelogenous_leukemia
gptkb:hairy_cell_leukemia
gptkb:COVID-19_(investigational)
gptkb:hepatitis_C
gptkb:hepatitis_B
multiple myeloma
follicular lymphoma
malignant melanoma
condyloma acuminatum
|
|
gptkbp:bfsParent
|
gptkb:HeberFERON
|
|
gptkbp:bfsLayer
|
7
|